Real-world data (RWD) is no longer a buzzword or something from the future. With the 21st Century Cures Act putting RWD in focus, and FDA guidance issued in January 2022 on its use in regulatory decision making, all functions within healthcare and life sciences need to understand the what, how, and when to use RWD for drug discovery, clinical development, and commercial use cases. At the same time, technology has advanced both in how data are collected and harmonized and in how data are delivered and ingested by data subscribers.

In this panel discussion, thought leaders from Qiagen, Prognos, TriNetX, and AWS will discuss the RWD landscape in 2022 including how data are being collected and harmonized in a secure and privacy-enabled way, top use cases being seen in biopharma, and how technology will play a role in RWD over the next five years.

Register now

You will learn:

• The importance of prioritizing R&D programs according to real-world need and opportunity
• Understanding how real-world data can inform eligibility, endpoints, and comparators for more patient-centric studies
• How to find patients based on documented or inferred clinical observations
• The benefits of generating evidence of real-world safety and effectiveness for patients, providers, regulators, and payors
• How to use Real World Data to improve pharmacovigilance